NCNA Stock Analysis: Buy, Sell, or Hold?
NCNA - NuCana plc American Depositary Share
$1.49
-0.03 (-1.97%)
âŧ
5d:
-3.87%
30d:
+15.5%
90d:
-26.24%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 19, 2026
0d
Get Alerted When NCNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NCNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NCNA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NCNA is currently trading at $1.49, which is considered slightly high relative to its 30-day fair value range of $1.29 to $1.50.
Technical Outlook: Technically, NCNA is in a strong downtrend. Immediate support is located at $1.40, while resistance sits at $1.67.
Market Sentiment: NCNA scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.00 (+6742.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NCNA is in a strong downtrend. Immediate support is located at $1.40, while resistance sits at $1.67.
Market Sentiment: NCNA scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $104.00 (+6742.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.29 -
$1.50
Company Quality Score
29/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 6742.1% below Wall St target ($104.00)
- WARNING: Composite score 28/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.29 -
$1.50
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.67
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.23
Wall Street Target
$104.00
(+6742.1%)
Share & Embed Analysis
Last updated: August 24, 2026 1:31 PM ET
Data refreshes hourly during market hours. Next update: 2:31 PM
Data refreshes hourly during market hours. Next update: 2:31 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NCNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
